Overview
Publication
Lancet HIV. 2018 Jul; 5(7):e366-e378.
PubMed ID: 29898870
Title
A phase 1/2 HIV-1 vaccine trial of a Subtype C ALVAC-HIV and Bivalent Subtype C gp120/MF59 vaccine regimen in low risk HIV uninfected South African adults
Authors
Bekker LG, Moodie Z, Grunenberg N, Laher F, Tomaras GD, Cohen KW, Allen M, Malahleha M, Mngadi K, Daniels B, Innes C, Bentley C, Frahm N, Morris DE, Morris L, Mkhize NN, Montefiori DC, Sarzotti-Kelsoe M, Grant S, Yu C, Mehra VL, Pensiero MN, Phogat S, DiazGranados CA, Barnett SW, Kanesa-thasan N, Koutsoukos M, Michael NL, Robb ML, Kublin JG, Gilbert PB, Corey L, Gray GE, McElrath MJ on behalf of the HVTN 100 Protocol Team
Abstract
Modest efficacy was reported for the HIV vaccine tested in the RV144 trial, which comprised a canarypox vector (ALVAC) and envelope (env) glycoprotein (gp120). These vaccine components were adapted to express HIV-1 antigens from strains circulating in South Africa, and the adjuvant was changed to increase immunogenicity. Furthermore, 12-month immunisation was added to improve durability. In the HIV Vaccine Trials Network (HVTN) 100 trial, we aimed to assess this new regionally adapted regimen for advancement to efficacy testing.
With the publicly available data in the CAVD DataSpace we can Learn about studies, products, assays, antibodies, and publications, Find subjects with common characteristics, Plot assay results across studies and years of research, and Compare monoclonal antibodies and their neutralization curves. Data are also accessible via DataSpaceR, our R API.
Sign in to see full information about this publication and to download study data when available.